Cancer and Rheumatic Diseases, An Issue of Rheumatic Disease Clinics of North America
- 1st Edition, Volume 46-3 - July 10, 2020
- Imprint: Elsevier
- Editor: John Davis
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 7 6 1 2 6 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 7 6 1 2 7 - 7
This issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteThis issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: rheumatic drugs and malignancy potential, biologic drugs and cancer, methotrexate and cancer, managing rheumatoid arthritis with cancer, Sjogren’s Syndrome and cancer, lupus and cancer, scleroderma and cancer, cancer and spondylarthritis, and cancer immunotherapy.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Rheumatic Disease Clinics of North America
- Foreword
- Preface
- Overview of the Associations Between Cancer and Rheumatic Disease
- Key points
- Introduction
- Overview of the associations between cancer and rheumatic disease
- Overview of shared risk factors
- Potential causal pathways from cancer to rheumatic disease
- Drug effects, cancer, and rheumatic disease
- Summary
- Clinics care points
- Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms
- Key points
- Introduction
- Rheumatologic association with myeloid neoplasms
- Summary
- Clinics Care Points
- Cancer and Rheumatoid Arthritis
- Key points
- Cancer risk in rheumatoid arthritis
- Cancer risk in rheumatoid arthritis in association with use of antirheumatic drugs
- Cancer screening in patients with cancer
- Safety of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and prior or concomitant cancer
- Recommendations on the management of rheumatoid arthritis in patients with cancer
- Use of corticosteroids in patients with rheumatoid arthritis and cancer
- Cancer treatment in patients with rheumatoid arthritis
- Summary
- Clinics care points
- Risk of Malignancy in Spondyloarthritis: A Systematic Review
- Key points
- Introduction
- Methods
- Risk for malignancy in psoriatic arthritis
- Risk of malignancy in ankylosing spondylitis
- Cancer and spondyloarthritis (combined axial spondyloarthritis and psoriatic arthritis)
- Association of pharmacotherapies for spondyloarthritis with cancer
- Risk of malignancy following therapeutics in spondyloarthritis with prior malignancy
- Other risk factors for cancer in spondyloarthritis
- Spondyloarthritis and cancer screening
- Considerations in interpretation of available data
- Clinics care points
- Summary
- Sjögren Syndrome and Cancer
- Key points
- General considerations
- Mucosa-associated lymphoid tissue lymphoma
- Other lymphomas and leukemias
- Multiple myeloma
- Lung cancer
- Thymus masses
- Skin cancer
- Other cancers, including breast
- Sarcoma
- Cancer therapy and Sjögren syndrome
- Summary
- Clinics Care Points
- Supplemental Table 1. Comparison of standardized incidence ratios for overall malignancy incidence in patients with Sjögren syndrome
- Supplemental Table 2. Studies of nonlymphoma malignancy in Sjögren syndrome
- Cancer and Systemic Lupus Erythematosus
- Key points
- Introduction
- Hematologic cancers
- Lung cancers
- Cervical and vulvar cancers
- Other cancers with increased risk
- Decreased cancer risk in systemic lupus erythematosus
- Summary
- Clinics care points
- Cancer and Scleroderma
- Key points
- Epidemiology of cancer in patients with scleroderma
- Potential mechanisms linking cancer and scleroderma
- Unique autoantibodies identify patient subgroups with a high risk of cancer-associated scleroderma
- Evidence for a model of cancer-induced autoimmunity
- Cancer protective immune responses may modify cancer risk in scleroderma
- Implications for cancer screening
- Summary
- Clinics care points
- Risk Factors and Cancer Screening in Myositis
- Key points
- Introduction
- Definition and timing of cancer-associated myositis
- Clinical and serologic risk factors for cancer associated myositis
- Serologic risk factors for cancer-associated myositis
- Proposed risk stratification based on myositis autoantibodies
- Screening strategies
- Approach to screening
- Summary
- Clinics care points
- Paraneoplastic Musculoskeletal Syndromes
- Key points
- Introduction
- Specific paraneoplastic syndromes
- Summary
- Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity
- Key points
- Introduction
- Immune-related adverse events
- Rheumatic immune-related adverse events
- Common rheumatic immune-related adverse events
- Life-threatening rheumatic immune-related adverse events
- Immune checkpoints—mechanism of action
- Cytotoxic T-lymphocyte–associated protein 4 and programmed death 1 and autoimmunity
- Summary
- Edition: 1
- Volume: 46-3
- Published: July 10, 2020
- Imprint: Elsevier
- Language: English
- Hardback ISBN: 9780323761260
- eBook ISBN: 9780323761277